Abstract: The disclosed embodiments provide a system for testing machine learning workflows. During operation, the system obtains a configuration for a staging test of a machine learning model, wherein the configuration includes a model name for the machine learning model, a duration of the staging test, and a use case associated with the machine learning model. Next, the system selects a staging test host for the staging test. The system then deploys the staging test on the staging test host in a staging environment, wherein the deployed staging test executes the machine learning model based on live traffic received from a production environment. After the staging test has completed, the system outputs a set of metrics representing a system impact of the machine learning model on the staging test host.

Abstract: The disclosed embodiments provide a system for testing machine learning workflows. During operation, the system obtains a configuration for a staging test of a machine learning model, wherein the configuration includes a model name for the machine learning model, a duration of the staging test, and a use case associated with the machine learning model. Next, the system selects a staging test host for the staging test. The system then deploys the staging test on the staging test host in a staging environment, wherein the deployed staging test executes the machine learning model based on live traffic received from a production environment. After the staging test has completed, the system outputs a set of metrics representing a system impact of the machine learning model on the staging test host.

Abstract: An aqueous pharmaceutical composition suitable for oral delivery has an insoluble active substance and one or more wetting agents in liquid suspension. The composition contains floccules of the active ingredient and is substantially free of polyethelyne glycol, propylene glycol, glycerol and sorbitol. The formulation has an excellent shelf-life in which caking and sedimentation are inhibited. The composition may be resuspended upon light to moderate shaking.

Abstract: An aqueous pharmaceutical composition suitable for oral delivery has an insoluble active substance and a wetting agent in liquid suspension. The composition contains floccules of the active ingredient. The formulation has an excellent shelf-life in which caking and sedimentation are inhibited. The composition may be resuspended upon light to moderate shaking.

Abstract: An aqueous pharmaceutical composition suitable for oral delivery has an insoluble active substance and one or more wetting agents in liquid suspension. The composition contains floccules of the active ingredient and is substantially free of polyethelyne glycol, propylene glycol, glycerol and sorbitol. The formulation has an excellent shelf-life in which caking and sedimentation are inhibited. The composition may be resuspended upon light to moderate shaking.

Abstract: An aqueous pharmaceutical composition suitable for oral delivery has an insoluble active substance and a wetting agent in liquid suspension. The composition contains floccules of the active ingredient. The formulation has an excellent shelf-life in which caking and sedimentation are inhibited. The composition may be resuspended upon light to moderate shaking.

Abstract: Anhydrous vehicles for topical use, e.g. for use with topically active pharmaceutical agents, including antibiotics, anti-fungal agents, anti-inflammatory agents, antihistamines, antipruritics and local anesthetics, comprise principally from about 60 to about 90% by weight of at least one glycol solvent and from about 2 to about 20% by weight etherified saturated fatty alcohol having a total chain length of from 20 to 216 carbon atoms. The vehicles are substantially free of water, greasy substances and fatty alcohols having less than 16 carbon atoms. The vehicles have a cream-like consistency and can also incorporate suitable compatible plasticizers, coupling agents, penetrants and the like.